MA56187A - Traitements de l'angio-oedème héréditaire - Google Patents

Traitements de l'angio-oedème héréditaire

Info

Publication number
MA56187A
MA56187A MA056187A MA56187A MA56187A MA 56187 A MA56187 A MA 56187A MA 056187 A MA056187 A MA 056187A MA 56187 A MA56187 A MA 56187A MA 56187 A MA56187 A MA 56187A
Authority
MA
Morocco
Prior art keywords
treatments
hereditary angioedema
angioedema
hereditary
Prior art date
Application number
MA056187A
Other languages
English (en)
Other versions
MA56187B1 (fr
Inventor
Edward Paul Feener
Andreas Maetzel
Sally Louise Marsh
Michael David Smith
Christopher Martyn Yea
Original Assignee
Kalvista Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalvista Pharmaceuticals Ltd filed Critical Kalvista Pharmaceuticals Ltd
Publication of MA56187A publication Critical patent/MA56187A/fr
Publication of MA56187B1 publication Critical patent/MA56187B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
MA56187A 2019-07-15 2020-06-15 Traitements de l'angio-oedème héréditaire MA56187B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1910116.1A GB201910116D0 (en) 2019-07-15 2019-07-15 Treatments of hereditary angioedema
PCT/GB2020/051439 WO2020249977A1 (fr) 2019-06-14 2020-06-15 Traitements de l'angio-oedème héréditaire

Publications (2)

Publication Number Publication Date
MA56187A true MA56187A (fr) 2022-04-20
MA56187B1 MA56187B1 (fr) 2023-09-27

Family

ID=67700145

Family Applications (1)

Application Number Title Priority Date Filing Date
MA56187A MA56187B1 (fr) 2019-07-15 2020-06-15 Traitements de l'angio-oedème héréditaire

Country Status (34)

Country Link
US (1) US20220218680A1 (fr)
EP (2) EP4282474A3 (fr)
JP (3) JP7356518B2 (fr)
KR (1) KR102748728B1 (fr)
CN (1) CN114126612A (fr)
AR (1) AR119158A1 (fr)
AU (1) AU2020293614B2 (fr)
BR (1) BR112021024664A2 (fr)
CA (1) CA3142218A1 (fr)
CL (2) CL2021003244A1 (fr)
DK (1) DK3982960T3 (fr)
EA (1) EA202193019A1 (fr)
ES (1) ES2956471T3 (fr)
FI (1) FI3982960T3 (fr)
GB (1) GB201910116D0 (fr)
HR (1) HRP20230696T1 (fr)
HU (1) HUE063163T2 (fr)
IL (1) IL288615A (fr)
LT (1) LT3982960T (fr)
MA (1) MA56187B1 (fr)
MD (1) MD3982960T2 (fr)
MX (1) MX2021014557A (fr)
MY (1) MY205687A (fr)
PH (1) PH12021552966A1 (fr)
PL (1) PL3982960T3 (fr)
PT (1) PT3982960T (fr)
RS (1) RS64412B1 (fr)
SG (1) SG11202113304YA (fr)
SI (1) SI3982960T1 (fr)
SM (1) SMT202300261T1 (fr)
TW (1) TW202112370A (fr)
UA (1) UA129869C2 (fr)
WO (1) WO2020249977A1 (fr)
ZA (1) ZA202110685B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
GB201910116D0 (en) * 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of hereditary angioedema
CN114206852A (zh) 2019-08-09 2022-03-18 卡尔维斯塔制药有限公司 血浆激肽释放酶抑制剂
WO2022084693A1 (fr) * 2020-10-23 2022-04-28 Kalvista Pharmaceuticals Limited Traitements de l'oedème de quincke
WO2022172006A1 (fr) 2021-02-09 2022-08-18 Kalvista Pharmaceuticals Limited Traitements de l'angio-oedème héréditaire
CA3255900A1 (fr) 2022-04-27 2023-11-02 Kalvista Pharmaceuticals Limited Formulations d'un inhibiteur de la kallicréine plasmatique
CN116003386B (zh) * 2022-11-20 2024-03-26 药康众拓(北京)医药科技有限公司 一种氘代n-苄基吡啶酮吡唑甲酰胺类化合物、药物组合物和用途
WO2025172693A1 (fr) 2024-02-13 2025-08-21 Kalvista Pharmaceuticals Limited Sebetralstat oral pour le traitement d'un épisode d'angio-œdème héréditaire
WO2025172692A1 (fr) 2024-02-13 2025-08-21 Kalvista Pharmaceuticals Limited Sebetralstat à administrer par voie orale pour le traitement d'une attaque d'angioedème héréditaire
WO2026003532A1 (fr) 2024-06-28 2026-01-02 Kalvista Pharmaceuticals Limited Sébetralstat pour le traitement de l'anxiété associée à un angioedème héréditaire

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
GB9019558D0 (en) 1990-09-07 1990-10-24 Szelke Michael Enzyme inhibitors
SE9301911D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptide derivatives
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
GB0205527D0 (en) 2002-03-08 2002-04-24 Ferring Bv Inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
JP5322935B2 (ja) 2006-07-31 2013-10-23 アクティベサイト ファーマシューティカルズ インコーポレイティッド 血漿カリクレインの阻害薬
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
JP2013121919A (ja) 2010-03-25 2013-06-20 Astellas Pharma Inc 血漿カリクレイン阻害剤
ES2483802T3 (es) 2010-07-07 2014-08-07 The Medicines Company (Leipzig) Gmbh Inhibidores de serina proteasa
WO2012009009A2 (fr) 2010-07-14 2012-01-19 Addex Pharma S.A. Nouveaux dérivés de 2-amino-4-pyrazolyl-thiazole et leur utilisation en tant que modulateurs allostériques des récepteurs métabotropiques du glutamate
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
GB2494851A (en) 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
ES2909885T3 (es) 2013-05-23 2022-05-10 Kalvista Pharmaceuticals Ltd Inhibidores de la calicreína plasmática
EP2815749A1 (fr) * 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Forme solide de 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione ayant un réseau de diffraction de rayons X spécifique
EP2886107A1 (fr) * 2013-12-17 2015-06-24 ObsEva S.A. Formules orales de dérivés de pyrrolydine
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201721515D0 (en) * 2017-12-21 2018-02-07 Kalvista Pharmaceuticals Ltd Dosage forms comprising a plasma kallikrein inhibtor
GB201910116D0 (en) * 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of hereditary angioedema

Also Published As

Publication number Publication date
AU2020293614B2 (en) 2024-08-15
CN114126612A (zh) 2022-03-01
WO2020249977A1 (fr) 2020-12-17
HRP20230696T1 (hr) 2023-10-13
PT3982960T (pt) 2023-09-26
HUE063163T2 (hu) 2023-12-28
EA202193019A1 (ru) 2022-03-24
AR119158A1 (es) 2021-12-01
MA56187B1 (fr) 2023-09-27
JP2022536287A (ja) 2022-08-15
PL3982960T3 (pl) 2024-01-15
DK3982960T3 (da) 2023-08-21
CA3142218A1 (fr) 2020-12-17
SG11202113304YA (en) 2021-12-30
ZA202110685B (en) 2024-06-26
IL288615A (en) 2022-02-01
CL2021003244A1 (es) 2022-09-30
AU2020293614A1 (en) 2022-01-27
MD3982960T2 (ro) 2023-12-31
JP2023166406A (ja) 2023-11-21
ES2956471T3 (es) 2023-12-21
TW202112370A (zh) 2021-04-01
KR102748728B1 (ko) 2024-12-30
PH12021552966A1 (en) 2022-07-25
CL2023000639A1 (es) 2023-10-30
EP3982960A1 (fr) 2022-04-20
MY205687A (en) 2024-11-06
BR112021024664A2 (pt) 2022-05-31
EP3982960B1 (fr) 2023-06-28
EP4282474A2 (fr) 2023-11-29
NZ782935A (en) 2025-02-28
SMT202300261T1 (it) 2023-09-06
EP4282474A3 (fr) 2024-02-14
LT3982960T (lt) 2023-08-25
JP7356518B2 (ja) 2023-10-04
MX2021014557A (es) 2022-01-11
JP2025124716A (ja) 2025-08-26
RS64412B1 (sr) 2023-09-29
JP7688078B2 (ja) 2025-06-03
FI3982960T3 (fi) 2023-08-29
UA129869C2 (uk) 2025-08-27
SI3982960T1 (sl) 2023-10-30
US20220218680A1 (en) 2022-07-14
GB201910116D0 (en) 2019-08-28
KR20220024220A (ko) 2022-03-03

Similar Documents

Publication Publication Date Title
MA56187A (fr) Traitements de l'angio-oedème héréditaire
IL277333A (en) Methods for treating eye diseases
PT3873604T (pt) Métodos para tratar a doença de alzheimer com hp-[beta]-ciclodextrina
MA49295A (fr) Traitements du cancer de l'utérus
MA55607A (fr) Inducteurs de la ho-1
IL289485A (en) Neurodegenerative disease therapies utilizing the skin-brain axis
IL287168A (en) Kit of pyrrolotriazine derivatives for the treatment of diseases mediated by pdgfra
IL280315A (en) Methods of treatment and prevention of alzheimer's disease
MA56188A (fr) Traitements de l'oedème de quincke
IL285110A (en) Methods of treating multiple myeloma
EP3751048A4 (fr) Agent de traitement de fibres
LT4034122T (lt) Hiperfenilalaninemijos gydymo būdai
IL289436A (en) Methods for treating ocular diseases
ZA202107235B (en) Compositions and methods for treating ocular disease
IL286663A (en) Hydrogel
EP3870699A4 (fr) Traitements pour la maladie de charcot-marie-tooth
SG11202110659SA (en) Method for treating ocular diseases
PL4009942T3 (pl) Związek służący do leczenia skojarzonego
EP3773461A4 (fr) Traitements modifiés pour la réparation des cheveux et la rétention de couleur durable
EP4247165A4 (fr) Traitements respiratoires
EP3789075C0 (fr) Dispositif pour traitements cosmétiques
EP3988645A4 (fr) Procédé de décellularisation
EP3758702A4 (fr) Traitement de l'oedème de quincke héréditaire
KR102090101B9 (ko) 구강 질환 예방 또는 치료용 조성물
EP3930415C0 (fr) Procédé d'accès aléatoire